• SPX
  • $5,952.12
  • 0.06 %
  • $3.41
  • DJI
  • $44,121.70
  • 0.57 %
  • $251.34
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,263.78
  • 1.41 %
  • $114.51
  • IXIC
  • $18,918.19
  • -0.29 %
  • -$54.23
Adial Pharmaceuticals, Inc. (ADIL) Stock Price, News & Analysis

Adial Pharmaceuticals, Inc. (ADIL) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.01

-$0.01

(-0.98%)

Day's range
$1
Day's range
$1.02
50-day range
$0.9355
Day's range
$1.28
  • Country: US
  • ISIN: US00688A2050
52 wk range
$0.77
Day's range
$4.17
  • CEO: Mr. Cary John Claiborne MBA
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -15.13
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (ADIL)
  • Company Adial Pharmaceuticals, Inc.
  • Price $1.01
  • Changes Percentage (-0.98%)
  • Change -$0.01
  • Day Low $1.00
  • Day High $1.02
  • Year High $4.17

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/27/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$4.98
  • Trailing P/E Ratio -0.25
  • Forward P/E Ratio -0.25
  • P/E Growth -0.25
  • Net Income $-7,001,890

Income Statement

Quarterly

Annual

Latest News of ADIL

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Adial Pharmaceuticals, Inc. Frequently Asked Questions

  • What were the earnings of ADIL in the last quarter?

    In the last quarter Adial Pharmaceuticals, Inc. earnings were on Wednesday, November, 13th. The Adial Pharmaceuticals, Inc. maker reported -$0.38 EPS for the quarter, beating analysts' consensus estimates of -$0.50 by $0.12.

  • What is the Adial Pharmaceuticals, Inc. stock price today?

    Today's price of Adial Pharmaceuticals, Inc. is $1.01 — it has decreased by -0.98% in the past 24 hours. Watch Adial Pharmaceuticals, Inc. stock price performance more closely on the chart.

  • Does Adial Pharmaceuticals, Inc. release reports?

    Yes, you can track Adial Pharmaceuticals, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Adial Pharmaceuticals, Inc. stock forecast?

    Watch the Adial Pharmaceuticals, Inc. chart and read a more detailed Adial Pharmaceuticals, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Adial Pharmaceuticals, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Adial Pharmaceuticals, Inc. stock ticker.

  • How to buy Adial Pharmaceuticals, Inc. stocks?

    Like other stocks, ADIL shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Adial Pharmaceuticals, Inc.'s EBITDA?

    Adial Pharmaceuticals, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Adial Pharmaceuticals, Inc.’s financial statements.

  • What is the Adial Pharmaceuticals, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Adial Pharmaceuticals, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Adial Pharmaceuticals, Inc.'s financials relevant news, and technical analysis. Adial Pharmaceuticals, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Adial Pharmaceuticals, Inc. stock currently indicates a “sell” signal. For more insights, review Adial Pharmaceuticals, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.